Drug Profile
Sym 022
Alternative Names: Anti-LAG-3 - Symphogen; S 95017; Sym022Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator Symphogen
- Developer Servier; Symphogen
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD223 antigen inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
- No development reported Lymphoma
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Canada (IV, Infusion)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Lymphoma(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (IV, Infusion)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in Canada (IV, Infusion)